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Abstract
Background: End stage liver disease (ESLD) is associated with significant thrombotic complications. In this study,
we attempted to determine if patients with ESLD, due to oncologic or autoimmune diseases, are susceptible to
thrombosis to a greater extent than patients with ESLD due to other causes.
Methods: In this retrospective study, we analyzed the UNOS database to determine the incidence of thrombotic
complications in orthotopic liver transplant (OLT) recipients with autoimmune and oncologic conditions.
Between 2000 and 2012, 65,646 OLTs were performed. We found 4,247 cases of preoperative portal vein thrombosis
(PVT) and 1,233 cases of postoperative vascular thrombosis (VT) leading to graft failure.
Results: Statistical evaluation demonstrated that patients with either hepatocellular carcinoma (HCC) or autoimmune
hepatitis (AIC) had a higher incidence of PVT (p = 0.05 and 0.03 respectively). Patients with primary biliary cirrhosis (PBC),
primary sclerosing cholangitis (PSC) and AIC had a higher incidence of postoperative VT associated with graft failure
(p < 0.0001, p < 0.0001, p = 0.05 respectively). Patients with preoperative PVT had a higher incidence of postoperative
VT (p < 0.0001). Multivariable logistic regression demonstrated that patients with AIC, and BMI ≥40, having had a
transjugular intrahepatic portosystemic shunt, and those with diabetes mellitus were more likely to have preoperative
PVT: odds ratio (OR)(1.36, 1.19, 1.78, 1.22 respectively). Patients with PSC, PBC, AIC, BMI ≤18, or with a preoperative PVT
were more likely to have a postoperative VT: OR (1.93, 2.09, 1.64, 1.60, and 2.01, respectively).
Conclusion: Despite the limited number of variables available in the UNOS database potentially related to thrombotic
complications, this analysis demonstrates a clear association between autoimmune causes of ESLD and perioperative
thrombotic complications. Perioperative management of patients at risk should include strategies to reduce the
potential for these complications.
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Background
Orthotopic liver transplantation (OLT) for patients with
end-stage liver disease (ESLD) has become a standard-
ized procedure with an acceptable 5-year survival in the
majority of established liver transplantation programs in
the world. Despite significant improvements in all as-
pects of patient management, OLT is associated with a
number of complications affecting patient outcome. One
of the most significant complications is a perioperative
vascular thrombotic event (PVTE). PVTE is associated
with an increased mortality and morbidity in each stage
of perioperative management. PVTE is not infrequently
the cause of postoperative graft failure [1–3].
In this study we analyzed a number of factors poten-
tially associated with PVTE.
Retrospective analysis of United Network for Organ
Sharing (UNOS) data was performed to evaluate the effect
of oncologic and autoimmune diseases on the incidence of
perioperative vascular thrombotic complications in pa-
tients undergoing OLT. An association between oncologic
and autoimmune conditions and an increased risk of
thrombosis in general is well known [4–7]. Combining
these disorders with ESLD potentially enhances the likeli-
hood of a patient developing a hypercoagulable state. In
addition, statistical analysis was performed to determine
the role of other factors in the development of pre- or
postoperative thrombotic events.
Methods
The study was approved by the Institutional Review
Board at the Penn State Hershey Medical Center.
In this retrospective study, we analyzed the incidence
of thrombotic complications in adult deceased donor LT
recipients using the UNOS database. Overall, 119,663
liver transplantations performed in the US between 1993
and 2012 were available for review. Due to incomplete
data, only OLTs performed between 2000 and 2012 were
evaluated in the study. Patients younger than 15 years
old and patients who received living donor liver trans-
plantation were excluded from data collection.
We evaluated the association between PVTE and con-
ditions known to be associated with a hypercoagulable
state:
1. Hepatocellular Carcinoma (HCC)
2. Primary Biliary Cirrhosis (PBC)
3. Primary Sclerosing Cholangitis (PSC)
4. Autoimmune Cirrhosis (AIC)
Thrombotic complications identified in the database
included:
1. Preoperative portal vein thrombosis (PVT)
2. Postoperative vascular thrombosis (VT) as a cause
of graft failure (type of vascular complication was
not defined in the database)
Analysis included:
1. The association between oncologic and autoimmune
conditions and preoperative PVT.
2. The association between oncologic and autoimmune
conditions and postoperative VT.
3. The association between pre- and postoperative
thrombotic events
Additionally, multivariable logistic regression analysis
of PVTE predictive factors was performed. The variables
used for multivariable logistic regression were chosen
based on expert opinion and previously published data
describing factors associated with thrombosis in this pa-
tient population. Only a limited number of variables
were included in the analysis due to the limited availably
of data in the UNOS database.
Statistics
SAS version 9.3 (SAS Institute, Cary, NC) was used to
conduct all the data management and analyses. The
Pearson Chi-square test was used to test for differences
in incidence proportions of both thrombosis outcomes
across discrete clinical and demographic characteristics.
A two-tailed t-test was used to test for differences in
outcomes across continuously distributed recipient
characteristics.
Two multivariable logistic regression models for each
of the outcomes were developed. The initial selection of
variables to include in the models was performed by
expert clinician opinion and a review of the literature
for factors associated with thrombosis during liver
transplantation. Using a step-wise selection method
with a probability threshold cutoff of 0.05, the following
variables were dropped from the models: creatinine,
international ratio of prothrombin, bilirubin, indicator
whether patient had dialysis within two weeks prior to
transplant (MELD score components), warm and cold
ischemia times, donor’s age, ABO mismatch, HCC,
HCC and cirrhosis, and other cirrhosis. PSC and PBC
were only dropped from the portal vein thrombosis
model. Both models controlled for regional and tem-
poral variations by including time and region indicator
variables. The Bayes Information Criterion was used to
select the final models.
Results
We evaluated 62,441 OLTs performed between 2000 and
2012. Statistical analysis was performed to determine any
association between PVTE and the following autoimmune
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and oncologic conditions: a) HCC (n = 1,956), b) HCC
and cirrhosis (n = 3,205) (HCC and HCC with cirrhosis
were separately listed in the database), c) PBC (n = 2,103),
d) AIC (n = 1,746), and e) PSC (n = 3,030). UNOS data
related to thrombotic complications for this time inter-
val included: 1) preoperative PVT at the time of trans-
plant (n = 4,247), and 2) postoperative VT leading to
graft failure (n = 1,233). Demographics and incidence of
thrombotic events are demonstrated in Table 1.
A significantly higher incidence of preoperative PVT
was found in patients with HCC and AIC in comparison
to other patient populations (p = 0.05 and p = 0.03 re-
spectively). A high incidence of postoperative VT was
found in patients with PBC, PSC (p < 0.0001), and AIC
(p = 0.05). In addition, patients having had a preoperative
PVT had a significantly higher incidence of postopera-
tive VT (p < 0.0001).
Multivariable logistic regression analysis demonstrated
a number of significant associations (Table 2). Patients
with AIC, obese patients with a BMI above 40, patients
with diabetes mellitus (DM), and those having had a
TIPS, were more likely to have had a preoperative PVT
(OR 1.36, 1.19, 1.22 and 1.78 respectively).
Postoperative VT were highly associated with AIC,
PSC, and PBC (OR 1.64, 1.93, and 2.09 respectively). Pa-
tients having had a preoperative PVT were more likely
to have had a postoperative VT (OR 2.01). In addition,
patients with a BMI ≤18 also had an increased risk of
postoperative VT (OR 1.6).
Considering the very strong association between TIPS
and PVT, additional bivariate analysis was performed on
the data for this patient population.
There were 5,658 patients having had a TIPS at the
time of transplant. Overall, there was a significantly
higher incidence of patients having had a TIPS who had
a PVT (8.48 % vs. 4.05 %, p < 0.0001). Stratifying data for
patients having had a TIPS with respect to the cause
of liver failure demonstrated that the combination of
TIPS with AIC had a higher incidence of PVT as com-
pared to patients without TIPS and AIC (19.4 % vs. 8.4 %,
p < 0.0001).
Discussion
Our study demonstrates that autoimmune conditions are
strongly associated with PVTE. A possible association be-
tween oncologic conditions and PVT was also found. In
addition, PVT at the time of transplantation was a strong
predictive factor for the development of postoperative VT.
Chronic liver disease is associated with thrombotic
complications throughout the perioperative period with
the overall incidence of venous thrombosis varying be-
tween 0.5 and 6.3 % [8–10]. Hepatic artery thrombosis
specifically, was found in 3–9 % cases and usually oc-
curred after transplantation. It is, however, associated
with significant morbidity resulting in up to 53 % of all
post-transplant graft losses [2].
Another major factor contributing to perioperative mor-
bidity is PVT. The prevalence of PVT in liver transplant
Table 1 Demographic and clinical characteristics of the UNOS liver transplantation sample for the time interval 2000-2012 by portal
vein Thrombosis and graft failure ascribed to vascular thrombosis
Preoperative Portal Vein Thrombosis Postoperative Vascular Thrombosis
Demographic Characteristics Yes (N = 4,247) No (N = 61,399) P-value Yes (N = 1,233) No (N = 6,824) P-value
Age (year) 54.1 52.4 <0.0001* 49.8 50.5 0.04*
Sex (Male) (%) 2,952 (69.5 %) 40,893 (66.6 %) <0.0001* 834 (67.6 %) 4,559 (66.8 %) 0.58
BMI
Underweight (%) (BMI < 18.5 kg/m2) 104 (2.5 %) 1,498 (2.4 %) 0.97 51 (4.1 %) 173 (2.5 %) 0.002*
Overweight (%) (≥25 kg/m2) 1,418 (33.4 %) 21,605 (35.2 %) 0.018* 401 (32.5 %) 2,454 (36.0 %) 0.02*
Obese (%) (BMI≥ 30 kg/m2) 1,549 (36.5 %) 20,003 (32.6 %) <0.0001* 392 (31.8 %) 2,184 (32 %) 0.90
Clinical Factors
TIPSS (%) at the time of LTX 502 (11.8 %) 5,156 (8.4 %) <0.0001* 93 (7.5 %) 510 (7.5 %) 0.06
Portal Hypertensive Bleeding (%) at time of LTX 73 (8.8 %) 636 (4.4 %) <0.0001* 9 (2.8 %) 129 (6.7 %) 0.02*
Portal Vein Thrombosis (%) at the time of LTX – – – 136 (11.0 %) 373 (5.4 %) <0.0001*
Diabetes mellitus (%) 925 (23.9 %) 8,586 (15.5 %) <0.0001* 140 (12.7 %) 700 (11.7 %) 0.39
Autoimmune Cirrhosis (%) 135 (3.2 %) 1,607 (2.6 %) 0.03* 42 (3.8 %) 165 (2.7 %) 0.05*
Primary Sclerosing Cholangitis (%) – – – 97 (7.9 %) 288 (4.2 %) <0.0001*
Primary Biliary Cirrhosis (%) – – – 48 (4.3 %) 158 (2.6 %) 0.002*
Hepatocellular carcinoma (%) 146 (3.8 %) 1,809 (3.2 %) 0.05* 23 (2.0 %) 258 (2.5 %) 0.33
*p-values indicate a statistically significant difference at α = 0.05
LTX Liver transplantation
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candidates prior to transplantation is 8–25 % [11–13].
Post-transplant PVT occurs in 2–4 % of patients and is as-
sociated with significant postoperative mortality [1, 14].
Although the cause of PVTE is likely multifactorial,
hypercoagulability associated with ESLD is frequently
underestimated as a contributing factor. It has been
demonstrated that despite significant decreases in the
concentration of both coagulation and anticoagulation
factors, patients with ESLD have a compensatory in-
creased concentration of liver-independent factors such
as Factor VIII, von Willibrand factor (VWF), and Plas-
minogen Activator Inhibitor-1 (PAI-1) [15–19]. Both the
plasma level and activity of VWF and PAI-1 remain in-
creased up to 10 days after transplantation [14, 20, 21].
It has also been demonstrated that the concentration of
ADAMTS13 (protein responsible for splitting VWF) is
significantly decreased during and after OLT [21]. Taking
into consideration that modern platelet function tests have
failed to identify platelet dysfunction in patients with
ESLD [22], a VWF/ADAMTS13 imbalance might be
responsible for the hypercoagulability often seen in this
patient population [14, 21]. Other factors, such as in-
creased levels of thrombin [23], lipopolysaccharides and
tissue factor (TF), as well as resistance to thrombomodulin
[24, 25] also contribute to the hypercoagulable state seen
in patients with ESLD. This hypercoagulability is en-
hanced if the ESLD is caused by oncologic or autoimmune
diseases.
Our study demonstrates an increased incidence of pre-
operative PVT in patients with HCC. Previous investiga-
tions found the incidence of PVT in association with
HCC to be between 20 and 65 % [4, 5]. PVT after
transplantation in patients with HCC is also associated
with an increased mortality (OR 2.05, p = 0.004) [26, 27].
It has been suggested that increased TF expression
might be responsible for both PVT and systemic venous
thrombosis [26, 28, 29].
Our investigation demonstrated a significant association
between PBC, PSC, AIC, and postoperative VT. All these
conditions are autoimmune and include characteristics
contributing to hypercoagulability which include: chronic
inflammation (release of cytokines, expression of tissue
factors, endothelial dysfunction, inhibition of protein C),
increased levels of PAI-1 and antiphospholipid antibodies,
as well as a number of other factors such as elevated levels
of fibrinogen and TF [6, 7, 30–33].
It has been reported that preoperative PVT might be a
risk factor for recurrent postoperative thromboses result-
ing in an increased risk of re-transplantation [25, 34]. We
also found that preoperative PVT was associated with
postoperative thrombotic complications. It has been
suggested that an underlying hypercoagulability related
to rebalanced hemostasis might be responsible for this
phenomena [14].
Our study demonstrated a significant association be-
tween DM and PVT. Previous investigations have shown
an increased risk of venous thrombosis in patients with
DM [35, 36]. This finding is likely related to an increased
concentration of circulating microparticles, as well as ele-
vated thrombin and estrogen levels seen in patients with
DM [37, 38]. Taking into consideration that patients with
ESLD have elevated estrogen levels at baseline, the in-
crease seen in patients with ESLD and DM might contrib-
ute to the development of PVTE in this population.
Table 2 Multivariable logistic regression. UNOS liver transplantation sample for the time interval 2000-2012 by portal vein thrombosis
and graft failure ascribed to vascular thrombosis
Preoperative Portal Vein Thrombosis Postoperative Vascular Thrombosis
OR 95 % CI P-value OR 95 % CI P-value
Autoimmune Cirrhosis 1.36* 1.10—1.69 0.005* 1.64* 1.12—2.40 0.01*
Primary Biliary Cirrhosis – – – 2.09* 1.47—2.98 <0.0001*
Primary Sclerosing Cholangitis – – – 1.93* 1.48—2.51 <0.0001*
Portal Vein Thrombosis at the time of LTX – – – 2.01* 1.58—2.55 <0.0001*
Underweight (BMI < 18.5 kg/m2) 1.04 0.79—1.38 0.76 1.60* 1.07—2.40 0.02*
Obese (BMI≥ 40 kg/m2) 1.19* 1.08—1.31 0.0005* 1.00 0.83—1.19 1.00
Overweight (≥25 kg/m2) 1.05 0.96—.16 0.31 0.99 0.83—1.17 0.88
Normal Weight (18.5≥ BMI < 25) – – – – – –
Sex (Male) 1.09* 1.00—1.18 0.04* 1.00 0.86—1.17 0.97
Age (Year) 1.01* 1.01—1.02 <0.0001* 0.99 0.99—1.00 0.04
TIPSS at the time of LTX 1.78* 1.53—2.06 <0.0001* 0.82 0.57—1.16 0.25
Diabetes mellitus 1.22* 1.01—1.26 <0.0001* – – –
*Statistically significant at α = 0.05
LTX Liver transplantation
Note: This Model included the regions and year indicator variables to control for observed regional and temporal variations, the estimates are omitted for brevity
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There were a number of other important findings in
our investigation. Patients extremely over- or underweight
had a higher incidence of PVTE. The relationship between
obesity and thrombotic complications is well known
[39–45]. The association between thromboses and be-
ing underweight has not been previously described and
is most likely underappreciated. Pelletier, et al., found
that patients with a BMI ≤20 had a significantly higher
risk of death while on the transplant waiting list (OR = 1.61,
p < 0.0001) [46]. The cause of this phenomenon is not com-
pletely clear, but malnutrition-related mechanisms, such as
increased platelet aggregation with a concomitant elevation
in thromboxane A [47], and decreased vitamin B6 levels
resulting in hyperhomocysteinemia, might play an import-
ant role [48, 49]. The problems related specifically to being
underweight and having a liver transplant should be evalu-
ated more extensively in the future.
Recent publications have demonstrated that postoper-
ative thrombotic complications can be successfully pre-
vented using antithrombotic medications [50, 51]. Villa,
et al., demonstrated the effectiveness of enoxaparin in
preventing PVT in patients with advanced cirrhosis [50].
It has been shown that either aspirin administration [51]
or an infusion of low dose heparin [52] was effective in
the prevention of postoperative HAT. In their study, no
bleeding complications were observed.
Considering that autoimmune-related ESLD is associ-
ated with up to a twofold increased risk of perioperative
thrombotic complications, prophylaxis and treatment of
PVTE in patients at risk must be considered.
The relationship between TIPS and PVT has been previ-
ously demonstrated [53]. In our study, we also demon-
strated this association. TIPS placement for PVT treatment
was previously described in a small patient population as
an experimental procedure [54]. More recently, trans-
splenic portal vein recanalization in conjunction with TIPS
placement has been reported [55]. With the development
of this new TIPS procedure to treat PVT, some of the TIPS
placements listed in the database may have been inadvert-
ently included in our analysis of TIPS as the cause of PVT.
It is difficult to estimate how this may have affected our
statistical results. Considering that TIPS for PVT treatment
was established after 2012 and until now not performed
routinely in US centers, we expect the statistical impact to
be negligible. The association between TIPS and throm-
botic complications remains incompletely understood and
needs further evaluation.
Our analysis of the UNOS database has a number of
limitations.
Considering the retrospective character of this evaluation,
prospective randomized trials are necessary to establish
definitive recommendations for routine perioperative
antithrombotic prophylaxis for ESLD patients with
autoimmune conditions.
While performing this study, we found a significant
limitation in the structure of the UNOS database. The
number of potentially confounding factors, such as peri-
operative transfusion of blood products and coagulation
factors, the use of antifibrinolytics, intraoperative blood
loss, and type of surgical technique were not listed in
the database and could not be included in our statistical
analysis. Many transplant centers have independently
established protocols for perioperative anticoagulation.
This information was also not available for analysis. Al-
though these factors which were not included in the data
base may confound, to a limited extent, the effects of the
predictors included in our model, they would not change
the direction of our modeled effects nor impact the validity
of our results. Considering the significant statistical power
of this analysis and the large number of available variables
known to be related to thrombotic complications, we are
confident our results demonstrate a true clinical association
between autoimmune conditions and PVTE’s.
The type and timing of postoperative VT was not de-
fined in the database. Taking into consideration that only
VT’s resulting in graft failure were listed, the vast major-
ity of postoperative thromboses were likely related to
HAT as previously described [2]. Problems with the hep-
atic artery anastomosis are a common cause of HAT es-
pecially in the pediatric population [56]. Considering the
significant statistical power of our study, we assumed a
normal distribution of technical problems in all analyzed
patients and excluded pediatric patients. Taking into ac-
count these considerations, our results demonstrate an
increased postoperative VT risk in patients with auto-
immune conditions. More detailed risk stratification, in-
cluding the type of postoperative thrombotic complication,
may be obtained from future research.
Another limitation of the database is that only 2 types
of thrombotic complications were listed. This could re-
sult in the appearance of a disproportional incidence of
pre- and postoperative thrombosis in patients with PBC
and PSC. These autoimmune conditions can potentially
be associated with other types of thromboses such as
deep venous, pulmonary, and others not listed.
The limited types of thrombotic events listed might ac-
count for our finding that HCC was not associated with
thrombotic events. A significant number of patients with
HCC undergo transarterial chemoembolization (TACE).
This potentially results in arterial damage with subsequent
thrombosis [57]. In our investigation, however, we were
not able to demonstrate a relationship between HCC and
postoperative VT despite significant patient numbers.
Conclusion
Identifying factors contributing to thrombotic events as
well as the prevention of PVTE is of high importance.
In our study, we have demonstrated that autoimmune
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disorders, such as PBC, PSC and AIC, can lead to an
increased incidence of PVTE. Preoperative PVT is as-
sociated with postoperative thrombotic complications
that are likely related to an underlying hypercoagulable
state. Based on our results, postoperative antithrombotic
prophylaxis for patients with autoimmune disorders
undergoing OLT should be carefully considered.
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